Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2003;34:551-557
Published online before print January 9, 2003, doi: 10.1161/01.STR.0000054055.28435.BF
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/2/551    most recent
01.STR.0000054055.28435.BFv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gertz, K.
Right arrow Articles by Endres, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gertz, K.
Right arrow Articles by Endres, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*Statins
*Stroke
Related Collections
Right arrow Animal models of human disease
Right arrow Other Stroke Treatment - Medical
Right arrow Endothelium/vascular type/nitric oxide

(Stroke. 2003;34:551.)
© 2003 American Heart Association, Inc.


Original Contributions

Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice

Karen Gertz, MD; Ulrich Laufs, MD; Ute Lindauer, DVM; Georg Nickenig, MD; Michael Böhm, MD; Ulrich Dirnagl, MD Matthias Endres, MD

From the Klinik und Poliklinik für Neurologie, Charité, Humboldt-Universität Berlin, Berlin (K.G., U. Lindauer, U.D., M.E.), and Klinik für Kardiologie, Universität des Saarlandes, Homburg (U. Laufs, G.N., M.B.), Germany. Drs Gertz and Laufs contributed equally to this work.

Correspondence to Dr Matthias Endres, Klinik und Poliklinik für Neurologie, Schumannstrasse 20/21, 10117 Berlin, Germany. E-mail matthias.endres{at}charite.de

Background and Purpose— Statins (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase inhibitors) reduce stroke damage independent of lipid lowering by upregulation of endothelial nitric oxide synthase (eNOS). Acute withdrawal of statin treatment may suppress endothelial NO production and impair vascular function.

Methods— To test this hypothesis, we treated 129/SV mice with atorvastatin (10 mg/kg) for 14 days and then withdrew treatment.

Results— Treatment with atorvastatin conferred stroke protection by 40% after filamentous occlusion of the middle cerebral artery followed by reperfusion. Withdrawal of statin treatment, however, resulted in the loss of stroke protection after 2 and 4 days. In mouse aortas and brain vasculature, statins upregulated eNOS message 2.3- and 1.7-fold, respectively, as measured by reverse transcription–polymerase chain reaction. Withdrawal of statins resulted in 5- and 2.7-fold downregulation of eNOS in aorta and brain, respectively, after 2 days. Statin treatment decreased RhoA GTPase membrane expression to 48%, while withdrawal of statins resulted in 4-fold increase of RhoA in the membrane. Moreover, platelet factor 4 and ß-thromboglobulin in plasma were significantly downregulated by statin treatment, but withdrawal of statins resulted in a 2.9- and 3.1-fold upregulation after 2 days, respectively. Thrombus formation induced by ligature of the inferior vena cava was significantly reduced by statin treatment. When statin treatment was withdrawn, however, protection was lost between 2 and 4 days.

Conclusions— Acute termination of statin treatment results in a rapid loss of protection in mouse models of cerebral ischemia and thrombus formation independent of lipid lowering. In patients with acute or impending stroke, withdrawal of statins may impair outcome.


Key Words: cerebral ischemia • HMG-CoA reductase inhibitors • nitric oxide • thrombosis




This article has been cited by other articles:


Home page
ANGIOLOGYHome page
S. Westphal, C. Abletshauser, and C. Luley
Fluvastatin Treatment and Withdrawal: Effects on Endothelial Function
Angiology, October 1, 2008; 59(5): 613 - 618.
[Abstract] [PDF]


Home page
CMAJHome page
D. A. Redelmeier MD MSHSR, D. Thiruchelvam MSc, and N. Daneman MD
Delirium after elective surgery among elderly patients taking statins
Can. Med. Assoc. J., September 23, 2008; 179(7): 645 - 652.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Rosengarten, D. Auch, and M. Kaps
Effects of Initiation and Acute Withdrawal of Statins on the Neurovascular Coupling Mechanism in Healthy, Normocholesterolemic Humans
Stroke, December 1, 2007; 38(12): 3193 - 3197.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Blanco, F. Nombela, M. Castellanos, M. Rodriguez-Yanez, M. Garcia-Gil, R. Leira, I. Lizasoain, J. Serena, J. Vivancos, M. A. Moro, et al.
Statin treatment withdrawal in ischemic stroke: A controlled randomized study
Neurology, August 28, 2007; 69(9): 904 - 910.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
Y. Le Manach, G. Godet, P. Coriat, C. Martinon, M. Bertrand, M.-H. Fleron, and B. Riou
The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery
Anesth. Analg., June 1, 2007; 104(6): 1326 - 1333.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Hong, J.-S. Zeng, D. L. Kreulen, D. I. Kaufman, and A. F. Chen
Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2210 - H2215.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Endres and U. Laufs
Discontinuation of Statin Treatment in Stroke Patients
Stroke, October 1, 2006; 37(10): 2640 - 2643.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M.-Y. Tseng, M. Czosnyka, H. Richards, J. D. Pickard, and P. J. Kirkpatrick
Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage: A Phase II Randomized Placebo-Controlled Trial
Stroke, August 1, 2005; 36(8): 1627 - 1632.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. S.V. Elkind, A. C. Flint, R. R. Sciacca, and R. L. Sacco
Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality
Neurology, July 26, 2005; 65(2): 253 - 258.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. B. Singhal, M. A. Topcuoglu, D. J. Dorer, C. S. Ogilvy, B. S. Carter, and W. J. Koroshetz
SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage
Neurology, March 22, 2005; 64(6): 1008 - 1013.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Endres and U. Laufs
Effects of Statins on Endothelium and Signaling Mechanisms
Stroke, November 1, 2004; 35(11_suppl_1): 2708 - 2711.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. P. McGowan and for the Treating to New Target Study Group
There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients
Circulation, October 19, 2004; 110(16): 2333 - 2335.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Y. Streifler
Editorial Comment--Statins, Stroke Outcome, and Stroke Prevention: When Should We Start Treatment?
Stroke, May 1, 2004; 35(5): 1121 - 1123.
[Full Text] [PDF]